Development of a pathogenesis-based therapy for peeling skin syndrome type 1

Area of Science:

• Dermatology
• Genetics
• Biotechnology

Background:

• Peeling skin syndrome type 1 (PSS1) is a rare, severe autosomal recessive congenital ichthyosis.
• Characterized by erythroderma, pruritus, and generalized skin peeling due to CDSN gene mutations.
• Current therapies for PSS1 are inadequate, significantly impacting patient quality of life.

Purpose of the Study:

• To develop the initial phase of a protein replacement therapy for CDSN deficiency in PSS1.
• To restore CDSN function and enhance cell-cell cohesion in the epidermis.
• To investigate a novel therapeutic strategy for PSS1.

Main Methods:

• Recombinant expression of human corneodesmosin (CDSN) in E. coli.
• Development of a liposome-based carrier system with cationic lipopeptide for keratinocyte delivery.
• Characterization of liposomal system and investigation of its interaction with keratinocytes and epidermal equivalents.

Main Results:

• Liposomes effectively accumulated at keratinocyte membranes.
• CDSN-deficient epidermal equivalents treated with liposomal CDSN showed CDSN presence in the stratum granulosum.
• Improved epidermal integrity was observed in treated CDSN-deficient epidermal equivalents.

Conclusions:

• This study provides the first preclinical in vitro evidence for a targeted protein replacement therapy for PSS1.
• The developed liposomal CDSN delivery system shows potential for treating CDSN deficiency.
• Further research may lead to effective therapeutic options for PSS1 patients.